tiprankstipranks
Trending News
More News >
Assembly Biosciences (ASMB)
NASDAQ:ASMB

Assembly Biosciences (ASMB) AI Stock Analysis

Compare
551 Followers

Top Page

AS

Assembly Biosciences

(NASDAQ:ASMB)

Rating:62Neutral
Price Target:
$18.50
▲(1.98%Upside)
The overall stock score is driven by strong technical momentum and positive corporate developments from the recent trial results. However, significant financial challenges and negative valuation metrics weigh heavily on the score, reflecting underlying risks.
Positive Factors
Financial Investment
Gilead's latest equity investment, priced at a premium, raises Gilead's ownership of outstanding ASMB voting stock from approximately 19.9% to 29.9%.
Positive Drug Profile
ABI-5366's PK profile is supportive of once-weekly or once-monthly dosing, which is highly encouraging.
Potential Market Opportunity
ABI-6250's oral bioavailability is a key attribute, indicating the potential for once-daily oral dosing, possibly becoming the first oral chronic HDV treatment.
Negative Factors
Efficacy Uncertainty
There is current uncertainty on the efficacy of Assembly's programs including ABI-5366, ABI-4334, and ABI-6250, at a level that could potentially support their advancement towards regulatory approvals.
Operational Risks
Key risks include failed or equivocal trial results, unforeseen safety or tolerability issues, meaningful delays to expected timelines, and inability to sufficiently fund operations.
Timeline Delays
Data readout for ABI-5366, originally expected in the first half of 2025, has been delayed to Fall 2025.

Assembly Biosciences (ASMB) vs. SPDR S&P 500 ETF (SPY)

Assembly Biosciences Business Overview & Revenue Model

Company DescriptionAssembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
How the Company Makes MoneyAssembly Biosciences generates revenue primarily through strategic partnerships, collaborations, and licensing agreements with other pharmaceutical companies. These partnerships often involve upfront payments, milestone payments based on the achievement of certain clinical, regulatory, or sales objectives, and royalties on potential future sales of any successfully developed products. Additionally, the company may engage in research and development collaborations that provide funding to support its proprietary drug development programs. However, as a company heavily focused on R&D, Assembly Biosciences may still be in the phases of clinical trials and not yet generating significant revenue from product sales.

Assembly Biosciences Financial Statement Overview

Summary
Assembly Biosciences exhibits financial distress across key areas. The absence of revenue in recent years, combined with enduring net losses and negative cash flows, suggests significant profitability and liquidity challenges. While leverage remains low, declining equity and assets reflect potential financial instability, requiring strategic reassessment.
Income Statement
15
Very Negative
Assembly Biosciences has faced significant challenges with consistent revenue declines from $79.1M in 2020 to $0 in 2022 and 2024, indicating potential instability. The company has struggled with persistent net losses and negative profit margins, including a net profit margin of -100% in 2024. These factors highlight major profitability issues.
Balance Sheet
40
Negative
While the company maintains a reasonable equity ratio of 28% in 2024, indicative of some financial stability, the declining stockholders' equity from $240.6M in 2020 to $33.4M in 2024 raises concerns. A relatively low debt-to-equity ratio of 0.09 in 2024 suggests manageable leverage, but the shrinking equity indicates potential risk.
Cash Flow
25
Negative
Assembly Biosciences experiences significant volatility in free cash flow, with figures dropping sharply from $22.5M in 2023 to -$51.1M in 2024. The negative operating cash flow and free cash flow pose risks to future liquidity and financial health.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue32.15M28.52M7.16M0.006.25M79.11M
Gross Profit32.09M28.39M-41.74M-498.00K5.79M79.00M
EBITDA-44.50M-45.42M-64.20M-92.59M-91.93M-64.78M
Net Income-39.92M-40.18M-61.23M-92.07M-129.85M-59.53M
Balance Sheet
Total Assets99.02M119.17M136.82M101.79M191.06M283.25M
Cash, Cash Equivalents and Short-Term Investments91.03M112.08M130.25M91.61M146.63M216.41M
Total Debt3.02M3.09M2.34M3.46M6.48M10.13M
Total Liabilities71.88M85.81M95.73M19.13M22.13M42.68M
Stockholders Equity27.13M33.36M41.10M82.66M168.93M240.58M
Cash Flow
Free Cash Flow-56.21M-51.15M22.49M-84.56M-96.49M-65.18M
Operating Cash Flow-56.19M-51.12M22.74M-84.46M-93.40M-62.96M
Investing Cash Flow29.48M40.17M-69.14M90.64M26.52M68.07M
Financing Cash Flow31.37M29.45M13.82M614.00K53.06M7.60M

Assembly Biosciences Technical Analysis

Technical Analysis Sentiment
Positive
Last Price18.14
Price Trends
50DMA
14.64
Positive
100DMA
12.83
Positive
200DMA
14.36
Positive
Market Momentum
MACD
0.96
Positive
RSI
68.18
Neutral
STOCH
62.95
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ASMB, the sentiment is Positive. The current price of 18.14 is above the 20-day moving average (MA) of 17.18, above the 50-day MA of 14.64, and above the 200-day MA of 14.36, indicating a bullish trend. The MACD of 0.96 indicates Positive momentum. The RSI at 68.18 is Neutral, neither overbought nor oversold. The STOCH value of 62.95 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ASMB.

Assembly Biosciences Risk Analysis

Assembly Biosciences disclosed 29 risk factors in its most recent earnings report. Assembly Biosciences reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Assembly Biosciences Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
62
Neutral
$138.55M-133.65%148.33%42.41%
52
Neutral
$7.53B0.32-61.76%2.28%16.60%1.56%
$61.31M-20.33%
41
Neutral
$148.02M-46.04%39.58%
36
Underperform
$70.27M-55.68%-57.45%
32
Underperform
$33.85M-1372.59%20.85%
$69.50M-54.30%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
ASMB
Assembly Biosciences
18.14
4.29
30.97%
MNOV
Medicinova
1.25
-0.15
-10.71%
ABOS
Acumen Pharmaceuticals
1.16
-1.15
-49.78%
RANI
Rani Therapeutics Holdings
0.54
-3.06
-85.00%
VTYX
Ventyx Biosciences
2.08
-0.21
-9.17%
GNTA
Genenta Science SpA Sponsored ADR
3.80
0.57
17.65%

Assembly Biosciences Corporate Events

Product-Related AnnouncementsBusiness Operations and Strategy
Assembly Biosciences Reports Positive Phase 1b Trial Results
Positive
Jun 25, 2025

On June 25, 2025, Assembly Biosciences announced positive topline results from a Phase 1b clinical trial evaluating ABI-4334, a next-generation capsid assembly modulator, in participants with chronic hepatitis B virus infection. The trial demonstrated favorable safety, tolerability, and pharmacokinetics, supporting once-daily oral dosing. The results showed significant antiviral activity, with mean plasma HBV DNA reductions consistent across different dosage cohorts. These findings support the potential of ABI-4334 to inhibit viral replication and cccDNA formation, crucial for HBV treatment regimens. The completion of the trial triggers an opt-in point for collaboration with Gilead Sciences, Inc., which could impact future development and commercialization efforts.

The most recent analyst rating on (ASMB) stock is a Buy with a $29.00 price target. To see the full list of analyst forecasts on Assembly Biosciences stock, see the ASMB Stock Forecast page.

Executive/Board ChangesShareholder MeetingsBusiness Operations and Strategy
Assembly Biosciences Announces Stock Plan Amendments and Leadership Change
Neutral
Jun 9, 2025

At the Annual Meeting of Stockholders on June 5, 2025, Assembly Biosciences, Inc. announced the approval of amendments to its 2018 Stock Incentive Plan and Employee Stock Purchase Plan, increasing the number of shares reserved for issuance. These amendments aim to enhance the company’s retention grant program and support employee stock purchases, reflecting a strategic move to bolster employee engagement and retention. Additionally, Jeanette M. Bjorkquist was appointed as the principal financial officer, succeeding Jason A. Okazaki, who remains the principal executive officer. This management change signifies a continued focus on strengthening the company’s financial leadership.

The most recent analyst rating on (ASMB) stock is a Buy with a $29.00 price target. To see the full list of analyst forecasts on Assembly Biosciences stock, see the ASMB Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 26, 2025